Recent progress in targeted therapy for non-small cell lung cancer
The high morbidity and mortality of non-small cell lung cancer (NSCLC) have always been major threats to people’s health. With the identification of carcinogenic drivers in non-small cell lung cancer and the clinical application of targeted drugs, the prognosis of non-small cell lung cancer patients...
Main Authors: | Yanxia Xiao, Pu Liu, Jie Wei, Xin Zhang, Jun Guo, Yajun Lin |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-02-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1125547/full |
Similar Items
-
Using Technology for Learning: Generalizable Lessons from Educational Technology Integration in Kenya
by: Adeela Arshad-Ayaz, et al.
Published: (2023-01-01) -
Tyrosine Kinase Inhibitors Target B Lymphocytes
by: Nikki Lyn Esnardo Upfold, et al.
Published: (2023-02-01) -
Targeting KRAS in Non-Small Cell Lung Cancer
by: Elena Corral de la Fuente, et al.
Published: (2022-01-01) -
FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase
by: Jikui Guan, et al.
Published: (2015-09-01) -
Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy
by: Yuan Cheng, et al.
Published: (2021-12-01)